The released efficacy data from Allergan's (AGN) two Phase III trials of its anti-VEGF treatment abicipar in wet age-related macular degeneration looks to have exceeded the "unofficial benchmark set by potential extended-duration competitors," Novartis' (NVS) brolucizumab and Regeneron's (REGN) Eylea, Wells Fargo analyst David Maris tells investors in a research note. The analyst forecasts $125M in sales for abicipar in its first year on the market in 2020 and estimates it will grow to $500M in 2022. Maris keeps an Outperform rating on Allergan with a $240 price target.

Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.